Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2002

01-06-2002

The Sensitivity of MCF10A Breast Epithelial Cells to Alkylating Drugs is Enhanced by the Inhibition of O6-Methylguanine-DNA Methyltransferase Transcription with a Synthetic Double Strand DNA Oligonucleotide

Authors: Laura Mariani, Antonella Piccirilli, Lorenzo Citti, Maria Giovanna Colombo, Laura Poliseno, Giuseppe Rainaldi

Published in: Breast Cancer Research and Treatment | Issue 3/2002

Login to get access
Metadata
Title
The Sensitivity of MCF10A Breast Epithelial Cells to Alkylating Drugs is Enhanced by the Inhibition of O6-Methylguanine-DNA Methyltransferase Transcription with a Synthetic Double Strand DNA Oligonucleotide
Authors
Laura Mariani
Antonella Piccirilli
Lorenzo Citti
Maria Giovanna Colombo
Laura Poliseno
Giuseppe Rainaldi
Publication date
01-06-2002
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2002
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1015808205169

Other articles of this Issue 3/2002

Breast Cancer Research and Treatment 3/2002 Go to the issue

OriginalPaper

Thrombosis – a Clue of Poor Prognosis in Primary Non-Metastatic Breast Cancer?*

OriginalPaper

Identification of Breast Cancer-Restricted Antigens by Antibody Screening of SKBR3 cDNA Library Using a Preselected Patient's Serum

OriginalPaper

p53 Expression is Decreased in Primary Breast Carcinomas with Microsatellite Instability

Instructions for Authors

Instructions for Authors

OriginalPaper

Ductal Carcinoma in Situ of the Breast: a New Phenotype Classification System and its Relation to Prognosis

OriginalPaper

Quantitative Assessment of the Clavicle Radiostructure as a Tool for Estimation of the Osteopathic Effect of Breast Cancer Chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits